Log In
BCIQ
Print this Print this
 

FV-162

  Manage Alerts
Collapse Summary General Information
Company Fluorinov Pharma Inc.
DescriptionNext generation proteasome inhibitor
Molecular Target Proteasome
Mechanism of ActionProteasome inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$32.4M

$7.2M

$25.2M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/27/2016

$32.4M

$7.2M

$25.2M

Get a free BioCentury trial today